A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

EARLY_PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

BIOLOGICAL

GC022F

GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg.

Trial Locations (1)

Hebei Yanda Ludaopei Hospital, Sanhe